Please login to the form below

ZFN

This page shows the latest ZFN news and features for those working in and with pharma, biotech and healthcare.

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Sangamo’s specialises in the development of gene-editing drugs based on its zinc finger nuclease (ZFN) technology, which can be used to regulate the expression of genes but had disappointing

Latest news

Sangamo surges on data for haemophilia A gene therapy

nuclease (ZFN) gene-editing platform for rare disease Hunter syndrome.
Trial dents confidence in Sangamo’s gene-editing tech

now suggesting that it will have to switch its attention to a second generation of the ZFN design that it hopes will be more potent. ... whether this first generation of ZFNs will accomplish everything that patents need, particularly in the low- and
Editas CEO exits the CRISPR firm ahead of first clinical trial

Editas is one of several companies striving to develop new therapies based on CRISPR-Cas9 or other technologies – such as zinc finger nucleases (ZFN) or TALEN – that can modify genes in
Sangamo’s first gene-editing trial doesn’t convince investors

The US biotech presented data on the first four of six patients in an open-label study looking at three doses SB-913, a drug based on zinc finger nuclease (ZFN) ... Sangamo has a lot riding on the outcome of this study, as it wants to position its ZFN
Sangamo bulks up in cell therapy with TxCell acquisition

Sangamo’s zinc finger nuclease (ZFN) gene-editing technology is already being used to create chimeric antigen receptor T cell (CAR-T) cancer therapies under a $3b-plus deal with ... ZFN is a gene-editing approach that uses a DNA-cutting nuclease enzyme

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

2019: CRISPR and therapeutic gene editing comes of age

Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... to switch its attention to a second generation of the ZFN design that it hopes will be more potent.
Cutting through the noise: CRISPR

But other technologies are still very much in play. Chief among these are zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALEN).

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

PMHub

Add my company

Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story: ...
Working together to achieve better patient pathways: Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.: How design can lead improvement within Pharma...

Email:
Password:

Please login to the form below

ZFN

Subscribe to our email news alerts

Quick links